About: Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis
Creator	Cohen, Harvey Deshpande, Chetan Kanegaye, John Lau, Kenneth Lopez-Avila, Viorica Macaubas, Claudia Milojevic, Diana Schilling, James Xiao, Chris Burns, Jane Ling, Xuefeng Mellins, Elizabeth Park, Jane
source	PMC
abstract	PURPOSE: Systemic juvenile idiopathic arthritis is a chronic pediatric disease. The initial clinical presentation can mimic other pediatric inflammatory conditions, which often leads to significant delays in diagnosis and appropriate therapy. SJIA biomarker development is an unmet diagnostic/prognostic need to prevent disease complications. EXPERIMENTAL DESIGN: We profiled the urine peptidome to analyze a set of 102 urine samples, from patients with SJIA, Kawasaki disease (KD), febrile illnesses (FI), and healthy controls. A set of 91 plasma samples, from SJIA flare and quiescent patients, were profiled using a customized antibody array against 43 proteins known to be involved in inflammatory and protein catabolic processes. RESULTS: We identified a 17-urine-peptide biomarker panel that could effectively discriminate SJIA patients at active, quiescent, and remission disease states, and patients with active SJIA from confounding conditions including KD and FI. Targeted sequencing of these peptides revealed that they fall into several tight clusters from seven different proteins, suggesting disease-specific proteolytic activities. The antibody array plasma profiling identified an SJIA plasma flare signature consisting of tissue inhibitor of metalloproteinase-1 (TIMP1), interleukin (IL)-18, regulated upon activation, normal T cell expressed and secreted (RANTES), P-Selectin, MMP9, and L-Selectin. CONCLUSIONS AND CLINICAL RELEVANCE: The urine peptidomic and plasma protein analyses have the potential to improve SJIA care and suggest that SJIA urine peptide biomarkers may be an outcome of inflammation-driven effects on catabolic pathways operating at multiple sites. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12014-010-9058-8) contains supplementary material, which is available to authorized users.
has issue date	2010-09-30(xsd:dateTime)
bibo:doi	10.1007/s12014-010-9058-8
bibo:pmid	21124648
has license	no-cc
sha1sum (hex)	4b05e7b9898203b6bf0659c315eb9eb1f66f228c
schema:url	https://doi.org/10.1007/s12014-010-9058-8
resource representing a document's title	Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis
has PubMed Central identifier	PMC2970804
has PubMed identifier	21124648
schema:publication	Clin Proteomics
resource representing a document's body	covid:4b05e7b9898203b6bf0659c315eb9eb1f66f228c#body_text
is schema:about of	named entity 'TARGETED' named entity 'antibody' named entity 'profiled' named entity 'The' named entity 'febrile' named entity 'array' named entity 'identified' named entity 'KNOWN' named entity 'CLINICAL PRESENTATION' named entity 'SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS' named entity 'T CELL' named entity 'ACTIVE' named entity 'SAMPLES' named entity 'FLARE' named entity 'TISSUE INHIBITOR OF METALLOPROTEINASE-1' named entity 'CONDITIONS' named entity 'ANTIBODY ARRAY' named entity 'SEVEN' named entity 'PEPTIDOME' named entity 'APPROPRIATE' named entity 'PEPTIDE' named entity 'REMISSION' named entity 'RESULTS' named entity 'INVOLVED' named entity 'DISCRIMINATE' named entity 'MMP9' named entity 'BIOMARKER' named entity 'CUSTOMIZED' named entity 'A 17' named entity 'TO PREVENT' named entity 'DISEASE' named entity 'PROTEOLYTIC' named entity 'PURPOSE' named entity 'DEVELOPMENT' named entity 'CHRONIC' named entity 'LEADS' named entity 'IS A' named entity 'PATIENTS' named entity 'DIAGNOSTIC' named entity 'INITIAL' named entity 'THERAPY' named entity 'SJIA' named entity 'PEPTIDES' named entity 'SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS' named entity 'URINE' named entity 'THESE' named entity 'PEDIATRIC' named entity 'INCLUDING' named entity 'NEED' named entity 'PANEL' named entity '102' named entity 'PEDIATRIC DISEASE' named entity 'CATABOLIC' named entity 'REVEALED' named entity 'EXPRESSED' named entity 'PROCESSES' named entity 'P-SELECTIN' named entity 'TIGHT' named entity 'MONITORING' named entity 'FEBRILE' named entity 'PROTEIN ' named entity 'URINE' named entity 'DIAGNOSIS' named entity 'KAWASAKI DISEASE' named entity 'TARGETED SEQUENCING' named entity 'USING' named entity 'HEALTHY' named entity 'SIGNIFICANT' named entity 'PLASMA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software